Explore ›
Finding
Finding
improvement
Fenofibrate added to simvastatin increased HDL-C by 6.3% (from 0.98 to 1.05 mmol/l) and decreased triglycerides by 21.2% (from 1.85 to 1.37 mmol/l) at 1 year, with no difference in LDL-C between groups; however, the between-group difference in HDL-C narrowed to 1.7% by end of study due to improvements in the placebo group.
| Effect size | HDL-C +6.3%, triglycerides -21.2% |
| Follow-up | 1 year |
| Comparator | Placebo added to simvastatin (20-40 mg/day) |
| Effect summary | improvement; HDL-C +6.3%, triglycerides -21.2% |
Connected entities
Interventions
Conditions
Outcomes
Source
PMC4509601
The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus